米索前列醇用于开腹子宫肌瘤剔除术:随机对照试验的系统评价与荟萃分析
该系统评价与荟萃分析纳入8项随机对照试验共385例患者,其中192例术前接受米索前列醇。结果显示,与安慰剂相比,术前米索前列醇可显著减少开腹子宫肌瘤剔除术中的出血量、血红蛋白下降幅度、输血需求及手术时间,且不增加术后发热或延长住院时间。作者认为该低成本药物应在开腹子宫肌瘤剔除术前常规使用。
要点
- 术前米索前列醇较安慰剂减少开腹子宫肌瘤剔除术出血量170.32 ml。
- 术前米索前列醇较安慰剂降低血红蛋白下降0.48 g/dl并减少输血需求。
- 术前米索前列醇较安慰剂缩短手术时间11.64分钟,不增加术后发热或延长住院。
核心结论
- 中等至高质量研究证实,米索前列醇可最大限度减少开腹子宫肌瘤剔除术中的出血量和输血需求。
- 作者认为这种低成本且易获得的药物应在开腹子宫肌瘤剔除术前常规给药以改善临床结局。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、Cochrane、Scopus、MEDLINE和EMBASE。
- 纳入8项随机对照试验,共385例因症状性肌瘤行开腹子宫肌瘤剔除术的女性,其中192例术前接受米索前列醇。
- 使用修订版Cochrane随机试验偏倚风险评估工具评估偏倚风险,采用随机效应模型计算合并效应量及95%CI,并用两种统计模型分析数据。
主要发现
- 术前米索前列醇与安慰剂相比,出血量降低170.32 ml(95%CI -201.53至-139.10)。
- 术前米索前列醇与安慰剂相比,血红蛋白下降减少0.48 g/dl(95%CI -0.65至-0.31)。
- 术前米索前列醇与安慰剂相比,输血需求降低(OR -0.48,95%CI -0.65至-0.31)。
- 术前米索前列醇与安慰剂相比,手术时间缩短11.64分钟(95%CI -15.73至-7.54)。
- 术后发热和术后住院时间方面无差异。
临床怎么用
- 作者认为该低成本且易获得的药物应在开腹子宫肌瘤剔除术前常规给药以改善临床结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Excessive blood loss is a significant risk of myomectomy with the potential need for hysterectomy. OBJECTIVE: To study the effectiveness of preoperative misoprostol compared with placebo at open myomectomy on intra- and postoperative outcomes. SEARCH STRATEGY: PubMed, Cochrane, Scopus, MEDLINE and EMBASE. SELECTION CRITERIA: Randomised control studies of women undergoing open myomectomy for symptomatic fibroids who were given either misoprostol or placebo preoperatively. DATA COLLECTION AND ANALYSIS: The revised Cochrane risk-of-bias tool for randomised trials was used to assess the risk of bias. Primary outcomes were blood loss, drop in haemoglobin and need for blood transfusion. Secondary outcomes were operative time, postoperative pyrexia and length of postoperative stay. Pooled effect sizes with corresponding 95% CI were calculated using random effects models. Data were analysed using two statistical models for statistical reliability. RESULTS: Eight studies were included with a total of 385 patients, of which 192 received misoprostol. Preoperative misoprostol was significantly associated with lower blood loss by -170.32 ml (95% CI -201.53 to -139.10), lower drop in haemoglobin by -0.48 g/dl (95% CI -0.65 to -0.31), reduced need for blood transfusion (odds ratio [OR] -0.48, 95% CI -0.65 to -0.31), and a reduction in operative time by -11.64 minutes (95% CI -15.73 to -7.54). There was no difference in postoperative pyrexia or length of postoperative stay. CONCLUSION: Moderate- to high-quality studies have established that misoprostol minimises blood loss and need for blood transfusion at open myomectomy. This low-cost and readily available drug should be routinely administered prior to open myomectomy to improve clinical outcomes. TWEETABLE ABSTRACT: Use of misoprostol at open myomectomy reduces blood loss and need for blood transfusion with no impact on postoperative pyrexia.
引用
- Wali S, Balfoussia D, Touqmatchi D, et al. Misoprostol for open myomectomy: a systematic review and meta-analysis of randomised control trials. BJOG. 2020. PMID: 32613769. doi:10.1111/1471-0528.16389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。